Watch Ticker

AnaptysBio, Inc. Common Stock

Go to AnaptysBio, Inc. Common Stock Website

$23.48

-0.75 (-3.10%)

Live

Previous Close

$24.23

Day Range

$23.45 - $24.715

Previous Day Range

$24.07 - $25.61

Market Cap

$725.4 million USD

Day Vol.

229075

Previous Day Vol.

257276

Currency

USD

Primary Exchange

Nasdaq

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, inclu...

Community

0 posts discussing

0

Watchers

0

Visitors

Recent News

Delveinsight - Psoriasis Market Outlook in the 7MM Through 2034: In-Depth Analysis by Psoriasis Type | DelveInsight

The psoriasis pipeline has several drugs in mid- and late-stage development, including Imsidolimab, TAK-279, and Sonelokimab, which are expected to positively impact the market. The treatment landscape is expanding with new therapies from various companies.

Related tickers: ANAB, MLTX, EVLO.

Read Full Article

Eric Volkman - Why AnaptysBio Was Such a Healthy Stock This Week

AnaptysBio, a clinical-stage biotech company, has seen its stock price rise recently. A positive research note from Guggenheim analyst Yatin Suneja, who reiterated a buy rating and $75 price target, cites an upcoming phase 2 clinical trial readout for the company's atopic dermatitis drug and Sanofi's financial involvement as reasons for optimism.

Related tickers: ANAB, SNY.

Read Full Article

Trending Tickers

Please sign in to view